A fixed-dose lisinopril+amlodipine+rosuvastatin combination: prospects for its use in patients with hypertension and concomitant dyslipidemia


Cite item

Full Text

Abstract

In Russia, target blood pressure (BP) levels are achieved in only 14.4% of men and in 30.9% of women. The need for combination therapy of hypertension is as high as 70.7%. There are well-known benefits of combined antihypertensive therapy allowing for higher efficiency and better tolerability. One of the current combinations is a combination of an angiotensin-converting enzyme inhibitor and a calcium antagonist, which have pronounced protective activity and metabolic neutrality. Fixed-dose combinations have substantial advantages over free ones, contributing to improving patient compliance with the used treatment regimen. Dyslipidemia is present in 60.7% of the hypertensive patients. Nonetheless, only 9.7% of Russian patients with coronary heart disease take statins and control of lipid levels remains very poor. The review discusses whether the use of the triple combination lisinopril + amlodipine + rosuvastatin is reasonable from the standpoint of evidence-based medicine. There are literature data suggesting the high value of this fixed-dose combination in the context of organ protection and the reduced risk of cardiovascular events.

About the authors

V I Podzolkov

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

A E Bragina

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

K K Osadchiy

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

References

  1. Wald NJ and Law MR. A strategy to reduce cardiovascular disease by more than 80%. British Medical Journal. 2003;326(7407):1419. https://doi.org/10.1136/bmj.326.7404.1419
  2. Neaton JD, Wentworth D; for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,009 white men. Arch Intern Med. 1992;152:56-64.
  3. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В., Шальнова С.А., Яровая Е.Б., Конради А.О., Бойцов С.А., Кавешников В.С., Серебрякова В.Н., Трубачева И.А. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных АГ. Кардиология. 2014; 10: 4–12. https://doi.org/10.18565/cardio.2014.10.4-12
  4. Бойцов С.А., Лукьянов М.М., Якушин С.С., Марцевич С.Ю., Воробьев А.Н., Загребельный А.В., Переверзева К.Г., Правкина Е.А., Деев А.Д., Андреенко Е.Ю., Ершова А.И., Мешков А.Н., Мясников Р.П., Сердюк С.С., Харлап М.С., Базаева Е.В., Козьминский А.Н., Мосейчук К.А., Кудряшов Е.Н. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетанная сердечно-сосудистая патология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики. Кардиоваскулярная терапия и профилактика. 2014;13(6):44-50. https://doi.org/10.15829/1728-8800-2014-6-44-50
  5. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б., Белявская Д.В., Выдрина О.И., Пастернак Е.Ю., Белоусов Д.Ю. и группа исследователей. Фармакоэпидемиология артериальной гипертонии в России: анализ приверженности врачей (по результатам исследования ПИФАГОР IV). Системные гипертензии. 2015;12(1):19-25.
  6. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
  7. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646-661.
  8. Артериальная гипертензия. Под ред. Подзолкова В.И. М.: ООО «Издательство «Медицинское информационное агентство», 2016.
  9. Gupta A, Poulter N. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive drugs: a meta-analysis. Hypertension. 2010;55:399-407. https://doi.org/10.1161/HYPERTENSIONAHA.109.139816
  10. Jamerson KA, Weber MA.,Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, for the ACCOMPLISH Trial Investigation. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Eng J Med. 2008;359:2417-2428. https://doi.org/10.1056/NEJMoa0806182
  11. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
  12. Miyajima E, Shigemasa T, Yamada Y, Tochikubo O, Ishii M. Angiotensin II blunts, while an angiotensin-converting enzyme inhibitor augments, reflex sympathetic inhibition in humans. Clin Exp Pharmacol Physiol. 1999;26:797-802.
  13. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182-1187 https://doi.org/10.1016/S0002-9149(00)01199-1
  14. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5(2):95-110.
  15. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens. 1992;6(2):85-90.
  16. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998;13(3):564-569.
  17. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510. https://doi.org/10.1161/01.CIR.102.13.1503
  18. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-2225. https://doi.org/10.1001/jama.292.18.2217
  19. Rackel R, Bope E (eds). Conn’s Therapy. Phyladelphia: WB Saunders, 2003.
  20. Messerli FH, Grossman E. Pedal edema--not all dihydropyridine calcium antagonists are created equal. Am J Hypertens. 2002; 15(11):1019-1020.
  21. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial — Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentrerandomised controlled trial. Lancet 2005;366:895-906. https://doi.org/10.1016/S0140-6736(05)67185-1
  22. Bakris G, Briasoulis A, Dahlof B, Jamerson K, Weber MA, Kelly RY, Hester A, Hua T, Zappe D, Pitt B; ACCOMPLISH Investigators. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013;112(2):255-259. https://doi.org/10.1016/j.amjcard.2013.03.026
  23. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Narva AS, Ortiz E. 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. https://doi.org/10.1001/jama.2013.284427
  24. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351:28-31. https://doi.org/10.1016/S0140-6736(97)06209-0
  25. Pall D, Katona E, Juhasz M et al. Prevention of target organ damage with modern antihypertensive agents. Orv Hetil. 2006;147 (32):1505-1511.
  26. Недогода С.В., Чумачек Е.В, Ледяева А.А., Цома В.В., Саласюк А.С. Сравнительная эффективность фиксированных комбинаций лизиноприла с амлодипином и эналаприла с гидрохлортиазидом. Кардиоваскулярная терапия и профилактика. 2013;12(2):25-29. https://doi.org/10.15829/1728-8800-2013-2-25-29
  27. Остроумова О.Д., Первичко Е.И. Влияние фиксированной комбинации Экватор на уровень артериального давления и когнитивные функции у пожилых больных с артериальной гипертонией. Системные гипертензии. 2013;1:76-79.
  28. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentrerandomised controlled trial. Drugs. 2004; 64(S2):43-60. https://doi.org/10.1016/S0140-6736(03)12948-0
  29. Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160. https://doi.org/
  30. Crouse JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH et al. METEOR Study Group. Effect of rosuvastatin on progression of carotid intimamedia thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353. https://doi.org/10.1001/jama.297.12.1344
  31. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565. https://doi.org/10.1001/jama.295.13.jpc60002
  32. Ridker PM, Danielson E, Fonseca FA et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. https://doi.org/10.1056/NEJMoa0807646
  33. Карпов Ю.А., Лялина С.В. Исследование ТРИУМВИРАТ: снижение риска сердечно-сосудистых осложнений у пациентов c артериальной гипертонией с помощью тройной комбинации антигипертензивных и липидснижающих препаратов. Кардиология. 2015;9:10-15. https://doi.org/10.18565/cardio.2015.9.10-15
  34. Бланкова З.Н., Асланян Н.С., Смолянинова Н.Г., Агеев Ф.Т. Современный подход к лечению больных высокого сердечно-сосудистого риска: возможности комбинированной терапии. Системные гипертензии 2017;14(1):12-16.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies